| HOME >> MEDICINE >> TECHNOLOGY |
21,614—Stockholders’ Deficit:Common Stock, $.001 par value, 50,000,000 shares authorized, 7,028,059 shares issued and outstanding as of September 30, 2011; 4,791,102 shares issued and outstanding as of December 31, 2010;
75Additional paid-in capital
5,2064,312Deficit accumulated during the development stage
(49,855)(20,214)Total Stockholders’ Deficit
(44,642)(15,897)Total Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
$26,806$14,939CORONADO BIOSCIENCES, INC. AND SUBSIDIARY(A development stage enterprise)Condensed Consolidated Statements of Operations($ in thousands expect per share amounts)(Unaudited)For the three months endedFor the nine months endedSeptember 30, September 30, 2011
20102011
2010Operating expenses:Research and development
$1,753
$1,822$5,141
$6,341General and administrative
1,778
2603,965
510In-process research and development
—
—20,706
—Loss from operations
(3,531)
(2,082)(29,812)
(6,851)Interest income
70
24111
32Interest expense, net
(19)
(62)(55)
(1,535)Warrant income
115
—115
—Net loss
($3,365)
($2,120)($29,641)
($8,354)Common Stock dividend to Series A Convertible Preferred Stockholders
—
—(5,861)
—Net loss attributed to Common Stock
($3,365)
($2,120)($35,502)
($8,354)Basic and diluted net loss per common share
($0.48)
($0.44)($6.02)
($1.92)Weighted average common shares outstanding—basic and diluted
7,028,060
4,791,1025,897,462
4,349,345Contact Information:Investor Relations
Noah D. Beerman, Executive Vice President & Chief Operating Officer
Coronado Biosciences, Inc.
781-238-6619; '/>"/>
| SOURCE Coronado Biosciences, Inc. Copyright©2010 PR Newswire. All rights reserved |